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ORIGINAL ARTICLE
Scared to Death? Generalized Anxiety Disorder
and Cardiovascular Events in Patients
With Stable Coronary Heart Disease
The Heart and Soul Study
Elisabeth J. Martens, PhD; Peter de Jonge, PhD; Beeya Na, MPH; Beth E. Cohen, MD, MAS;
Heather Lett, PhD; Mary A. Whooley, MD
Context: Anxiety is common in patients with coronary
heart disease (CHD), but studies examining the effect of
anxiety on cardiovascular prognosis and the role of po-
tential mediators have yielded inconsistent results.
Objectives: To evaluate the effect of generalized anxi-
ety disorder (GAD) on subsequent cardiovascular events
and the extent to which this association is explained by
cardiac disease severity and potential behavioral or bio-
logical mediators.
Design:Prospective cohort study (Heart and Soul Study).
Setting: Participants were recruited between Septem-
ber 11, 2000, and December 20, 2002, from 12 outpa-
tient clinics in the San Francisco Bay Area and were fol-
lowed up until March 18, 2009.
Participants: One thousand fifteen outpatients with
stableCHD followedup for amean (SD) of 5.6 (1.8) years.
Main Outcome Measures: We determined the pres-
ence of GAD using the Diagnostic Interview Schedule.
Proportional hazards models were used to evaluate the
association ofGADwith subsequent cardiovascular events
and the extent to which this association was explained
by potential confounders and mediators.
Results:A total of 371 cardiovascular events occurreddur-
ing 5711 person-years of follow-up. The age-adjusted an-
nual rate of cardiovascular eventswas 9.6% in the 106 par-
ticipants with GAD and 6.6% in the 909 participants
without GAD (P= .03). After adjustment for demo-
graphic characteristics, comorbidconditions (includingma-
jor depressive disorder), cardiac disease severity, andmedi-
cation use, GAD remained associated with a 62% higher
rate of cardiovascular events (hazard ratio, 1.62; 95% con-
fidence interval, 1.11-2.37; P=.01). Additional adjust-
ment for a variety of potential behavioral and biological
mediators had little effect on this association (hazard ra-
tio, 1.74; 95% confidence interval, 1.13-2.67; P=.01).
Conclusions: In outpatients with CHD, a robust asso-
ciation betweenGADand cardiovascular eventswas found
that could not be explained by disease severity, health
behaviors, or biologicalmediators.HowGAD leads to poor
cardiovascular outcomes deserves further study.
Arch Gen Psychiatry. 2010;67(7):750-758
A MPLE EVIDENCE HAS DEM-onstrated a strong andconsistent association be-tween psychological fac-tors, such as stress and car-
diovascular health.1,2 These factors are
important contributors to health decre-
ments in initially healthy patients and in
patients with established coronary heart
disease (CHD).3 Efforts have been made
to understand how these factors contrib-
ute to CHD onset, progression, and prog-
nosis. Most of these efforts have been di-
rected toward depression, with several
meta-analyses demonstrating that depres-
sion is an independent risk factor for the
development of CHD in the general popu-
lation4,5 and a prognostic risk factor in pa-
tients with CHD.6,7 It is less clear whether
this increased risk of cardiac events ex-
tends to patients with other symptoms of
negative affect, such as anxiety.8,9
Compared with the extensive litera-
ture on depression in patients with CHD,
relatively few studies have examined the
role of anxiety. Symptoms of anxiety are
common inpatientswithCHD,with preva-
lence rates ranging from 24% to 31%.10-15
Several studies14,16,17 have found that anxi-
ety symptoms are predictive of disability,
increased physical symptoms, and worse
functional status and quality of life in pa-
tients with CHD. However, studies exam-
ining anxiety as a risk factor for futureCHD
events have yielded conflicting results.
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toms to be predictive of subsequent cardiac events, mor-
tality, and in-hospital complications11,18-21 in patients with
CHD, whereas others have found no association15,22-24 or
even a protective effect.25,26 In addition, the extent towhich
this increased risk is independent of potential confound-
ing factors and the role of potentialmediators has not been
determined.Moreover, only 1 previous study21 has evalu-
ated the cardiac prognostic importance of generalized anxi-
ety disorder (GAD); others have relied on self-reportmea-
surement of anxiety symptoms. GAD is common and
treatable and could, therefore, be an important modifi-
able risk factor in patients with CHD.
In a prospective cohort study of 1015 participantswith
stable CHD, we evaluated the independent effect of GAD
on subsequent cardiovascular events and the extent to
which this association was explained by differences in
demographic characteristics, comorbid conditions, car-
diac disease severity, and potential behavioral and bio-
logical mediators.
METHODS
The Heart and Soul Study was designed to determine how psy-
chological disorders lead to cardiovascular events in outpa-
tients with stable CHD.27 Patients in California were recruited
from2Department of VeteransAffairs (VA)medical centers (San
Francisco VAMedical Center and the VA Palo Alto Health Care
System), 1 university medical center (University of California,
San Francisco), and 9 public health clinics in the Community
Health Network of San Francisco. Patients were eligible to
participate if they had at least 1 of the following: a history ofmyo-
cardial infarction, angiographic evidence of at least 50% steno-
sis in 1 ormore coronary vessels, previous evidence of exercise-
induced ischemia using treadmill or nuclear testing, a history
of coronary revascularization, or a diagnosis of CHD docu-
mented by an internist or cardiologist. Between September 11,
2000, and December 20, 2002, a total of 1024 participants were
enrolled: 240 from the public health clinics, 346 from the uni-
versity medical center, and 438 from the VA medical centers.
All the participants completed a baseline examination that
included an interview, fasting venous blood sample collection,
a psychiatric interview, a questionnaire, echocardiography, ex-
ercise treadmill testing, 24-hour ambulatory electrocardiog-
raphy, and 24-hour urine collection. Of the 1024 participants
who completed the baseline examination, 3 did not complete the
diagnostic interview for anxiety, and we could not contact 6 in-
dividuals (1%) during follow-up, leaving 1015 for this analy-
sis. The protocol was approved by the appropriate institutional
review boards (Committee on Human Research, University of
California, San Francisco; Research andDevelopment Commit-
tee, VA Medical Center, San Francisco; Medical Human Sub-
jects Committee, Stanford University, Stanford, California; Hu-
man Subjects Committee, Veterans Affairs Palo AltoHealthCare
System, Palo Alto, California; and the Data Governance Board
of the Community Health Network, San Francisco). All partici-
pants provided written informed consent.
GENERALIZED ANXIETY DISORDER
We determined the presence of GAD during the past year using
the computerized Diagnostic Interview Schedule for DSM-IV.28
Computerized versions of theDiagnostic InterviewSchedule have
previously demonstrated acceptable validity and reliability.29,30
We also ascertained the presence of major depressive disorder
(MDD) using the computerized Diagnostic Interview Schedule
forDSM-IV. Participants with a major depressive episode in the
past month were informed of this diagnosis, were instructed to
discuss their symptoms with their primary care physician, and
were provided a list of local resources available for treatment.
BASELINE CARDIAC DISEASE SEVERITY
AND RISK FACTORS
Fasting venous blood sampleswere collected to determine low-
andhigh-density lipoproteincholesterol levels. Participants com-
pleted an exercise treadmill test according to a standard Bruce
protocol. Thosewhocouldnot continue the standardBrucepro-
tocol were switched to slower settings and were encouraged to
exercise for as long as possible. Exercise capacity was calcu-
lated as the total number ofmetabolic equivalent tasks achieved.
We performed resting and stress echocardiograms using an
ultrasound system (Acuson Sequoia; Acuson Siemens, Moun-
tain View, California) with a 3.5-MHz transducer. Before ex-
ercise, standard 2-dimensional parasternal long- and short-
axis and apical 2- and 4-chamber views were obtained and
planimetered using a computerized digitization system to de-
termine end diastolic and end systolic left ventricular volume
and to calculate left ventricular ejection fraction. At peak ex-
ercise, parasternal long- and short-axis andapical 2- and4-cham-
ber views were used to detect the development of left ventricu-
lar wall motion abnormalities. Inducible ischemia was defined
as the presence of new wall motion abnormalities at peak ex-
ercise that were not present at rest.
POTENTIAL BEHAVIORAL MEDIATORS
Smoking and alcohol use were determined by self-report ques-
tionnaire.31 To assess medication adherence, we asked, “In the
pastmonth, howoften did you take yourmedications as the doc-
tor prescribed?” Possible responseswere “all of the time (100%),”
“nearly all of the time (90%),” “most of the time (75%),” “about
half the time (50%),” or “less than half the time (50%).” We
definedmedication nonadherence as taking prescribedmedica-
tions 75% of the time or less.32 To assess physical activity, we
asked, “Which of the following statements best describes how
physically active you have been during the past month, that is,
done activities such as 15 to 20minutes of brisk walking, swim-
ming, general conditioning, or recreational sports?” Partici-
pants chose 1 of the following 6 categories: not at all active, a
little active (1-2 times per month), fairly active (3-4 times per
month), quite active (1-2 times perweek), very active (3-4 times
per week), or extremely active (5 times per week). Partici-
pantswho reported that theywere not at all or a little activewere
considered physically inactive. Self-report has been shown to be
a reliable, valid, and accurate method of assessing physical ac-
tivity.33-36 In particular, single-response items have demon-
strated excellent construct validity.35-37
POTENTIAL BIOLOGICAL MEDIATORS
Three-channel 24-hour ambulatory Holter electrocardiog-
raphy was used to assess heart rate variability,38 including the
standard deviation of 5-minute mean NN intervals (SDANN)
and the natural log of very low frequency power. We collected
24-hour urine samples to measure norepinephrine and corti-
sol excretion.Norepinephrinewas assessed bymeans of gas chro-
matography–mass spectrometry at Associated Regional andUni-
versity Pathologists Inc (Salt Lake City, Utah). Cortisol was
analyzed using radioimmunoassay or (owing to a change at the
Associated Regional and University Pathologists Inc labora-
tory) high-performance liquid chromatography–tandem mass
spectrometry.39,40
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We used high-pressure liquid chromatography with elec-
trochemical detection to assay whole-blood serotonin levels.41
High-sensitivity C-reactive protein (CRP) levels were mea-
sured using the Integra assay (Roche, Indianapolis, Indiana)
in the first 229 participants and (owing to a change at the labo-
ratory) the Extended Range assay (Beckman Coulter Ireland
Inc, Galway, Ireland) in the remaining samples.42 Blood levels
of 2 -3 fatty acids, docosahexaenoic acid and eicosapentae-
noic acid, were measured using capillary gas chromatography
as the percentage composition of total fatty acid methyl esters
in the red blood cell membranes.43
OTHER PATIENT CHARACTERISTICS
Age, sex, race, educational achievement, and medical history
were determined by means of self-report questionnaire. We
measured height and weight and calculated body mass index
(calculated as weight in kilograms divided by height in
meters squared). Participants were instructed to bring their
medication bottles to their appointment, and study person-
nel recorded all current medications. Medications were
categorized using Epocrates Rx (Epocrates Inc, San Mateo,
California).







Age, mean (SD), y 60 (11) 68 (11) .001
Male sex, No. (%) 71 (67) 761 (84) .001
White race, No. (%) 60 (57) 551 (61) .42
High school graduate, No. (%) 94 (89) 789 (87) .62
BMI, mean (SD) 29.3 (6.0) 28.3 (5.2) .07
Comorbid conditions, No. (%)
Major depressive disorder 85 (80) 137 (15) .001
Hypertension 81 (76) 637 (70) .18
Myocardial infarction 50 (47) 495 (55) .16
Diabetes mellitus 34 (32) 231 (25) .14
Congestive heart failure 16 (15) 162 (18) .50
Stroke 13 (12) 134 (15) .51
Cardiac disease severity and risk factors
Resting left ventricular ejection fraction, mean (SD) 0.64 (0.07) 0.61 (0.10) .01
Exercise capacity, mean (SD), MET 7.9 (3.6) 7.2 (3.3) .06
LDL-C, mean (SD), mg/dL 108.8 (37.8) 103.7 (33.2) .16
HDL-C, mean (SD), mg/dL 44.2 (15.0) 46.1 (14.0) .19
Inducible ischemia, No. (%) 18 (17) 210 (23) .18
Medication use, No. (%)
Aspirin 83 (78) 705 (78) .86
-Blocker 68 (64) 521 (57) .18
Renin-angiotensin system inhibitor 45 (42) 477 (52) .05
Selective serotonin reuptake inhibitor 27 (25) 70 (8) .001
Other antidepressant 26 (25) 52 (6) .001
Anxiolytic, benzodiazepine 19 (18) 64 (7) .001
Tricyclic antidepressant 12 (11) 32 (4) .001
Anxiolytic, nonbenzodiazepine 8 (8) 29 (3) .02
Potential biological mediators, mean (SD)
Heart rate variability, SDANN, ms 112.1 (36.7) 108.6 (36.0) .37
Heart rate variability, lnVLF, ms2 6.3 (0.8) 6.3 (0.9) .93
Serotonin in non-SSRI users, ng/mL 122.8 (72.8) 119.5 (67.7) .69
Cortisol, µg/d 34.5 (21.9) 39.0 (30.1) .17
Norepinephrine, µg/d 51.2 (25.3) 51.8 (26.7) .82
Log C-reactive protein, mg/L 0.65 (1.21) 0.72 (1.31) .64
Log -3 fatty acid, % DHAEPA 1.25 (0.49) 1.34 (0.43) .05
Potential behavioral mediators, No. (%)
Regular alcohol use 32 (30) 259 (28) .70
Current smoking 29 (27) 170 (19) .05
Medication nonadherence 19 (18) 64 (7) .001
Self-reported physical activity, No. (%)
Not at all active 19 (18) 169 (19)
.03
A little active, 1-2 times/mo 31 (29) 151 (17)
Fairly active, 3-4 times/mo 15 (14) 140 (15)
Quite active, 1-2 times/wk 15 (14) 139 (15)
Very active, 3-4 times/wk 14 (13) 202 (22)
Extremely active, 5 times/wk 12 (11) 105 (12)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); DHA, docosahexaenoic acid;
EPA, eicosapentaenoic acid; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; lnVLF, natural log of very low frequency
power; MET, metabolic equivalent task; SDANN, standard deviation of 5-minute mean NN intervals; SSRI, selective serotonin reuptake inhibitor.
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259; cortisol to nanomoles per liter, multiply by 27.588; C-reactive protein to
nanomoles per liter, multiply by 9.524; and norepinephrine to picomoles per liter, multiply by 5.911.
aNumbers may not sum to their respective subtotals due to missing data, and percentages may not sum to 100% due to rounding.
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CARDIOVASCULAR EVENTS
Between the baseline examination and the last day of fol-
low-up onMarch 18, 2009, we conducted annual follow-up in-
terviews with participants (or their proxies) by telephone ask-
ing specifically about hospitalization for “heart trouble.” For
any reported event, medical records, electrocardiograms, death
certificates, and coroner’s reports were retrieved and reviewed
by 2 independent blinded adjudicators. In the event of dis-
agreement, the adjudicators conferred, reconsidered their clas-
sification, and requested consultation from a third blinded ad-
judicator as necessary.
The outcome events were stroke, heart failure, myocardial
infarction, transient ischemic attack, and death. Heart failure
was defined as hospitalization for a clinical syndrome involv-
ing at least 2 of the following: orthopnea, third heart sound,
pulmonary rales, paroxysmal nocturnal dyspnea, elevated jugu-
lar venous pressure, and cardiomegaly or pulmonary edema on
chest radiography. These signs and symptoms must have rep-
resented a clear change from the usual clinical status.44 Stroke
was defined as a new neurologic deficit not known to be sec-
ondary to brain trauma, tumor, infection, or another cause.45,46
Nonfatal myocardial infarction was defined based on the pres-
ence of symptoms, electrocardiographic changes, and cardiac
enzymes using standard criteria.47,48 Transient ischemic attack
was defined as a focal neurologic deficit (in the absence of head
trauma) lasting more than 30 seconds and no longer than 24
hours, with rapid evolution of the symptoms to the maximal
level of deficit in less than 5minutes andwith subsequent com-
plete resolution.45,46 Deaths were confirmed by review of death
certificates and coroner’s reports.
STATISTICAL ANALYSIS
Baseline differences in characteristics between participants with
andwithout GADwere compared using t tests and 2 tests. Lev-
els of CRP and-3 fatty acid were log transformed because they
were not normally distributed. We estimated the risk of car-
diovascular events associated with anxiety disorder using Cox
proportional hazards models.
To evaluate whether a covariate changed the strength of as-
sociation between anxiety disorder and cardiovascular events,
we calculated the percentage change in the effect size (log haz-
ard ratio [HR]) for anxiety disorder before and after adjust-
ment for the potential confounder or mediator. To avoid any
artifact due to different sample sizes between the 2 nestedmod-
els, participants missing the covariate of interest were ex-
cluded from each comparison. We sequentially considered
demographic variables, including depression, comorbid con-
ditions, cardiac disease severity, use of medications, and po-
tential behavioral and biological mediators.49 Variables that re-
sulted in a more than 5% change in the effect size (log HR) for
GADwere considered confounders or potential mediators and
were included in the final multivariable models.50
We verified the proportional hazards assumption of these
models using log-minus-log survival plots and by checking for
secular patterns in scaled Schoenfeld residuals. We usedWald
tests to check for interactions of anxiety disorder with age, sex,
and MDD in age- and multivariable-adjusted models. Analy-
ses were performed using a statistical software program (SAS
version 9.2; SAS Institute Inc, Cary, North Carolina).
RESULTS
Of the 1015 participants, 106 (10.4%) met the criteria
for GAD in the past year. Compared with participants
who did not have GAD in the past year, those with GAD
were younger, more likely to be female, and more likely
to haveMDD (Table 1). GADwas associated with a bet-
ter left ventricular ejection fraction and greater renin-
angiotensin system inhibitor, anxiolytic, and antidepres-
sant drug use. Participants with GADhad lower-3 fatty
acid levels andweremore likely to smoke,were less physi-
cally active, and were less adherent to medications.
A total of 371 cardiovascular events occurred during
5711 person-years (mean [SD] of 5.6 [1.8] person-years)
of follow-up. The age-adjusted annual rate of cardiovas-
cular events was 9.6% in the 106 participants with GAD
and 6.6% in the 909 participants without GAD (HR, 1.43;
95%confidence interval [CI], 1.03-2.00;P=.03) (Table2).
After excluding the 222 patients with MDD, the age-
adjusted annual rate of cardiovascular events was 9.2% in
21 participants with GAD and 6.9% in 772 participants
without GAD (HR, 1.33; 95% CI, 0.69-2.59; P=.39).
POTENTIAL MEDIATORS
Several variables, including male sex, comorbid condi-
tions, left ventricular function, exercise capacity, renin-
angiotensin system inhibitor and antidepressant drug use,
medication nonadherence, physical activity level, heart
rate variability, and CRP level, met the criteria for po-
tential confounding or mediation (Table 3). Variables
that did not change the effect size for GAD by 5% ormore
included MDD, use of selective serotonin reuptake in-
hibitors or anxiolytics, body mass index, smoking, and
levels of serotonin, -3 fatty acids, and 24-hour excre-
tion of norepinephrine and cortisol (Table 3).
Table 2. Cardiovascular Events During Follow-up by Generalized Anxiety Disorder Status
Event
Events, Age-Adjusted Annual Rate,
No. (%)a
Age-Adjusted Hazard Ratio





Myocardial infarction 15 (3.4) 97 (1.9) 1.71 (0.98-2.99) .06
Stroke or transient ischemic attack 7 (1.5) 42 (0.8) 1.83 (0.81-4.15) .15
Heart failure 9 (2.0) 137 (2.5) 0.75 (0.38-1.48) .40
All-cause mortality 24 (5.0) 242 (4.1) 1.29 (0.85-1.98) .24
Any of these outcomes 39 (9.6) 332 (6.6) 1.43 (1.03-2.00) .03
Abbreviation: CI, confidence interval.
aValues represent the number of persons with anxiety and any of these specific events.
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When adjusted formale sex, comorbid conditions, car-
diac disease severity, andmedication use, GAD remained
associatedwith a 62%greater rate of cardiovascular events
(HR, 1.62; 95% CI, 1.11-2.37; P=.01). Additional adjust-
ment for potential behavioral and biologicalmediators, in-
cludingmedicationnonadherence, physical inactivity, heart
rate variability (SDANN), and log CRP level, did not sub-
stantially change this association (Table 4). In the final
model, GADwas associatedwith a 74% greater rate of car-
diovascular events (HR, 1.74; 95% CI, 1.13-2.67; P=.01)
(Table 5 and Figure). We found no evidence that the
association between GAD and cardiovascular events var-
ied by age, sex, or MDD (P for interaction .1 for all).
Given that smoking is a known major cardiovascular
risk factor, we conducted a sensitivity analysis by includ-
ing current smoking in the final model. This did not re-
sult in a change in the effect size of GAD. In addition,
adjustment for previous smoking did not change the effect
of GAD. We conducted a second sensitivity analysis by
including left ventricular ejection fraction as a dichoto-
mous variable (as45% and as55%) in the finalmodel.
Table 3. Change in the Strength of Association Between
Generalized Anxiety Disorder and Cardiovascular Eventsa
After Adjustment for Potential Confounders and Mediators
Covariate





High school graduate 0.8





Congestive heart failure 4.5
Diabetes mellitus −9.3
Major depressive disorder 0.4
Cardiac disease severity and risk factors
Resting left ventricular ejection fraction 31.4







Renin-angiotensin system inhibitor 12.0
Tricyclic antidepressant −10.9










Heart rate variability, SDANN 14.8
Heart rate variability, lnVLF −1.4
Serotonin level, among nonusers of SSRIs 1.6
Cortisol excretion 1.9
Norepinephrine excretion 0.4
Log C-reactive protein level 10.1
Log -3 fatty acid level −0.4
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; lnVLF, natural log of very low frequency
power; MET, metabolic equivalent task; SDANN, standard deviation of
5-minute mean NN intervals; SSRI, selective serotonin reuptake inhibitor.
aExpressed as the percentage change in the age-adjusted log hazard ratio.
bChanges greater than 5% were considered clinically important and were
included in subsequent multivariate regression models.
Table 4. Association Between Generalized Anxiety Disorder
and Subsequent Cardiovascular Eventsa With Sequential




Age, per 10-y increase 1.43 (1.03-2.00)
Plus male sex 1.54 (1.10-2.15)
Plus history of myocardial infarction and diabetes
mellitus
1.56 (1.11-2.19)
Plus left ventricular ejection fraction (per 10%
decrease) and exercise capacity, MET (per SD
decrease)
1.72 (1.19-2.48)
Plus use of renin-angiotensin system inhibitor,
tricyclic antidepressant, and other antidepressant
1.62 (1.11-2.37)
Plus potential behavioral mediators: medication
nonadherence and physical inactivity
1.52 (1.04-2.24)
Plus potential biological mediators: heart rate
variability (SDANN, per SD decrease) and log
C-reactive protein (per SD increase)
1.74 (1.13-2.67)
Abbreviations: CI, confidence interval; MET, metabolic equivalent task;
SDANN, standard deviation of 5-minute mean NN intervals.
aCardiovascular events were heart failure, myocardial infarction, stroke,
transient ischemic attack, or death.
bEach model includes the variables from the preceding row so that the
final model includes all the variables listed in this table.
Table 5. Fully Adjusted Model of the Association
Between Generalized Anxiety Disorder and Subsequent
Cardiovascular Eventsa in 767 Participants






Anxiety disorder 1.74 (1.13-2.67) .01
Age, per 10-y increase 1.57 (1.36-1.83) .001
Male sex 2.47 (1.57-3.90) .001
History of myocardial infarction 1.50 (1.15-1.97) .003
History of diabetes mellitus 1.38 (1.03-1.84) .03
Left ventricular ejection fraction,
per 10% decrease
1.32 (1.17-1.49) .001
Exercise capacity, MET, per SD
decrease
1.46 (1.23-1.73) .001
Renin-angiotensin system inhibitor 1.13 (0.87-1.48) .35
Tricyclic antidepressant 1.44 (0.85-2.42) .17
Other antidepressant 1.40 (0.88-2.22) .16
Medication nonadherence 2.83 (1.87-4.30) .001
Physical inactivity 1.24 (0.95-1.62) .12
Heart rate variability, SDANN,
per SD decrease
1.15 (1.00-1.33) .05
Log C-reactive protein level,
per SD increase
1.19 (1.04-1.37) .01
Abbreviations: CI, confidence interval; MET, metabolic equivalent task;
SDANN, standard deviation of 5-minute mean NN intervals.
aCardiovascular events were heart failure, myocardial infarction, stroke,
transient ischemic attack, or death.
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This did not result in a significant change in the effect
size of GAD.
COMMENT
In this prospective cohort study of more than 1000 out-
patients with stable CHD, participants with baselineGAD
had a greater rate of subsequent cardiovascular events
(stroke, heart failure, myocardial infarction, transient is-
chemic attack, ordeath) thandidparticipantswithoutGAD.
Despite evaluating a variety of potential mediators, in-
cluding cortisol, norepinephrine, andCRP levels; heart rate
variability; smoking;medicationnonadherence; andphysi-
cal inactivity, the association between GAD and cardio-
vascular events could not be explained. Even after adjust-
ment for these and other variables, GAD remained
associatedwith a 74%greater rate of cardiovascular events.
This study is unique in its focus on the relationship of
GAD to cardiovascular events in outpatients with stable
CHD.Weare aware of only 1previous study that has evalu-
ated the cardiac prognostic importance of GAD. Frasure-
Smith and Lespe´rance21 demonstrated that GAD indepen-
dently predicted cardiac events in 804 patients with acute
coronary syndrome, but the extent to which the associa-
tion was explained by potential behavioral and biological
mediators was not assessed. Other studies11,15,18-26 exam-
ining the impact of anxiety on cardiac prognosis have re-
lied on self-reportmeasurements of anxiety symptoms and
have varied in patient populations, sample size, length of
follow-up, and ability to control covariates.
We previously found that the association between de-
pressive symptoms and cardiovascular events was largely
explained by poor health behaviors, especially physical in-
activity, in depressed patients with CHD.28 However, de-
spite an exhaustive search for potential mediators, we did
not identify the reason for an increased risk of cardiovas-
cular events associatedwith anxiety disorder. Several stud-
ies have demonstrated that anxiety is linked to patho-
logic mechanisms involved in CHD events,51 including
indicators of autonomicdysfunction, such as reducedbaro-
flex cardiac control and reduced heart rate variability,52-55
increased catecholamine levels56 andplatelet activity,57 dys-
regulation of the serotonin system,58 and markers of in-
flammation and coagulation.59 Thus, we were surprised
that biological mediators, such as heart rate variability
(SDANN), norepinephrine level, and inflammation (CRP
level), did not explain the increased risk associated with
anxiety disorder in the present study. Similarly, impor-
tant health behaviors, including smoking,medication ad-
herence, and physical activity, were not responsible for the
increased risk of cardiovascular events.
This leaves the question ofwhyGAD is associatedwith
adverse outcomes in patients with CHD. One possibility
is that anxiety may be associated with surges in catechol-
amines, which are, in turn, related to poor CHD progno-
sis. Although we collected urine samples to measure lev-
els of catecholamines and foundno associationwithGAD,
it is possible that using 24-hour specimens did not allow
us to capture these fluctuations. Another possibility is that
anxious patients with CHDmay be less likely to seek pre-
ventive medical care, possibly due to an avoidant coping
strategy. Benninghoven et al60 found that patients with
higher anxiety levels had worse medication compliance
and less contact with their cardiologists. Patients who are
less likely to seek preventive care could be at increased
risk for subsequent events.Alternatively, patientswith anxi-
ety could be more likely to seek care and receive a diag-
nosis of stroke ormyocardial infarction, and, thus, the in-
creased risk of events could bedue to greater ascertainment
in patients with anxiety. However, this would not ex-
plain their increasedmortality. It is also possible that there









0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96
Months, No.
Months, No.
Anxiety disorder, No. at risk


































































Figure. Cumulative risk of cardiovascular events stratified by the presence or absence of generalized anxiety disorder in an age-adjusted model (A) and in a model
fully adjusted for potential confounders and mediators (B) in 767 participants with complete data on all covariates.
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and risk of cardiovascular disease. The interplay of ge-
netic factors or the programming effects of fetal or post-
natal growth patterns may play a role. Further research
to determine themechanisms responsible for the relation-
ship between GAD and prognosis is warranted.
Wealso considered thepossibility that depression could
have interacted with anxiety and, thus, affected the rela-
tionship found between GAD and cardiovascular events.
Anxiety and depression are highly comorbid disorders in
psychiatric populations and in individuals with chronic
medical conditions, includingheart disease.61-64 In thepres-
ent study, 80% of patients with GAD had comorbid de-
pressive disorder. However, adjusting for major depres-
sion did not change the effect of GAD on cardiovascular
events, and we found no evidence of an interaction be-
tweenGADanddepression.Therefore, theprognostic value
of GAD seems to be independent of depressive disorder.
This finding is consistent with 2 previous studies11,19 that
found anxiety to be a significant predictor of cardiovas-
cular events after adjustment for depression.
Finally, GADwas associated with lower-3 fatty acid
levels. There is a clear association between dietary fac-
tors resulting in lower levels of -3 fatty acids and in-
creased CHD risk.65,66 In addition, a recent study43 found
a strong association between low-3 fatty acid levels and
depression in outpatients with stable CHD. Although-3
fatty acid levels did not affect the strength of association
between GAD and cardiovascular events, this is a poten-
tially interesting avenue to explore.
This study has several strengths, including detailed as-
sessments ofGADandcardiacdisease severity, carefulmea-
surement of potential behavioral and biological media-
tors, and comprehensive assessment of cardiovascular
events. However, several limitations must also be consid-
ered. First, most of the participants were older men, and
almost halfwere recruited fromVAmedical centers. There-
fore, these resultsmay not generalize towomenor to other
patient populations. Second, the associated riskwithGAD
may have been the result of greater cardiac disease sever-
ity. We attempted to address this possibility by carefully
measuring and adjusting for comorbid conditions and car-
diovascular disease severity. However, no observational
study can completely eliminate confounding, and it re-
mains possible that the effect of GAD on cardiovascular
outcomesmayhave been affected byworse underlying car-
diac disease severity that was not otherwise accounted for
in the models. Third, this study was limited to outpa-
tients with stable CHD, and, thus, we cannot comment on
the mechanisms of association between anxiety and car-
diovascular outcomes in healthy populations or in pa-
tients after acute coronary syndrome. Fourth, we did not
account for other anxiety disorders, such as specific pho-
bias, panic disorder, or posttraumatic stress disorder. In
addition, the high comorbidity between GAD and MDD
couldalsomean thatminorvariantsofdepressionarepreva-
lent that we did not account for in the analyses. Fifth, we
had no information on the time frame between the quali-
fying CHD event and the assessment of GAD except that
it was at least 6 months before enrollment.
Despite these limitations, these findings have implica-
tions for clinical practice and research. GADmay be con-
sidered a prognostic factor in patientswithCHDand could
be used in risk stratification. Evaluation and treatment of
anxiety may also be considered as part of the comprehen-
sive management of patients with CHD. Research pro-
grams designed to advance our understanding of the im-
pact of GADs on medical prognosis and biobehavioral
mechanisms that link anxiety to mortality in the context
of CHD are needed to develop evidence-based approaches
to improving patient care. In particular, randomized clini-
cal trials will be necessary to determine whether pharma-
cologic and behavioral interventions to reduce anxietywill
result in better CHD outcomes. Themanagement of anxi-
ety in patients with CHD may also require the develop-
ment of collaborative and integrative approaches combin-
ing medical and psychological expertise.
In summary, we found a strong and robust associa-
tion between GAD and cardiovascular events that could
not be explained by disease severity, health behaviors,
or biological mediators. The results of this study indi-
cate the need for future research to identify the under-
lying processes by which GAD contributes to adverse
events in patients with CHD and to test interventions to
alleviate this increased risk.
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